StockData
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT) stock

RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11+0.00 (0.00%)

Close on Nov 18, 2026Market cap $231.62MP/E –Yield –

Rocket Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Rocket Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$191.64M. For fiscal 2025 it was -$231.75M. The highest annual figure on record is -$7.57M in fiscal 2016.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$231.75M–
FY2024Dec 31, 2024-$273.21M–
FY2023Dec 31, 2023-$259.66M–
FY2022Dec 31, 2022-$224.34M–
FY2021Dec 31, 2021-$167.25M–
FY2020Dec 31, 2020-$134.30M–
FY2019Dec 31, 2019-$76.15M–
FY2018Dec 31, 2018-$71.16M–
FY2017Dec 31, 2017-$19.77M–
FY2016Dec 31, 2016-$7.57M–
FY2015Dec 31, 2015-$20.40M–
FY2014Dec 31, 2014-$7.70M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$46.92M–
Q1 FY2026Mar 31, 2026-$48.51M–
Q4 FY2025Dec 31, 2025-$43.96M–
Q3 FY2025Sep 30, 2025-$52.25M–
Q2 FY2025Jun 30, 2025-$71.15M–
Q1 FY2025Mar 31, 2025-$64.39M–
Q4 FY2024Dec 31, 2024-$62.69M–
Q3 FY2024Sep 30, 2024-$69.42M–
Q2 FY2024Jun 30, 2024-$73.71M–
Q1 FY2024Mar 31, 2024-$67.38M–
Q4 FY2023Dec 31, 2023-$63.28M–
Q3 FY2023Sep 30, 2023-$65.43M–
Q2 FY2023Jun 30, 2023-$68.76M–
Q1 FY2023Mar 31, 2023-$62.19M–
Q4 FY2022Dec 31, 2022-$69.08M–
Q3 FY2022Sep 30, 2022-$58.49M–
Q2 FY2022Jun 30, 2022-$54.21M–
Q1 FY2022Mar 31, 2022-$42.56M–
Q4 FY2021Dec 31, 2021-$44.33M–
Q3 FY2021Sep 30, 2021-$49.65M–
Q2 FY2021Jun 30, 2021-$34.05M–
Q1 FY2021Mar 31, 2021-$39.22M–
Q4 FY2020Dec 31, 2020-$59.24M–
Q3 FY2020Sep 30, 2020-$27.39M–
Q2 FY2020Jun 30, 2020-$23.56M–
Q1 FY2020Mar 31, 2020-$24.12M–
Q4 FY2019Dec 31, 2019-$19.65M–
Q3 FY2019Sep 30, 2019-$19.17M–
Q2 FY2019Jun 30, 2019-$18.39M–
Q1 FY2019Mar 31, 2019-$18.95M–
Q4 FY2018Dec 31, 2018-$26.55M–
Q3 FY2018Sep 30, 2018-$15.33M–
Q2 FY2018Jun 30, 2018-$14.87M–
Q1 FY2018Mar 31, 2018-$14.41M–
Q4 FY2017Dec 31, 2017-$6.66M-130.2%
Q3 FY2017Sep 30, 2017-$6.73M–
Q2 FY2017Jun 30, 2017-$3.52M–
Q1 FY2017Mar 31, 2017-$2.87M–
Q4 FY2016Dec 31, 2016$22.07M–
Q3 FY2016Sep 30, 2016-$10.72M–

More Rocket Pharmaceuticals figures

See a number that looks wrong?